• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy.

作者信息

Rizzo Jason M, Fecher Leslie A, Chan May P, Durham Alison B

机构信息

Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan.

Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.

出版信息

JAAD Case Rep. 2018 Apr 4;4(4):379-381. doi: 10.1016/j.jdcr.2018.01.023. eCollection 2018 May.

DOI:10.1016/j.jdcr.2018.01.023
PMID:29693076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5911974/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93b9/5911974/cf93b07394a1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93b9/5911974/a8c38db3af3e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93b9/5911974/cf93b07394a1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93b9/5911974/a8c38db3af3e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93b9/5911974/cf93b07394a1/gr2.jpg

相似文献

1
Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy.在对talimogene laherparepvec治疗产生稳定反应后，组织学上表现为伴有弥漫性黑变病的转移性黑色素瘤。
JAAD Case Rep. 2018 Apr 4;4(4):379-381. doi: 10.1016/j.jdcr.2018.01.023. eCollection 2018 May.
2
The safety of talimogene laherparepvec for the treatment of advanced melanoma.talimogene laherparepvec治疗晚期黑色素瘤的安全性。
Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28.
3
Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.替莫唑胺胶囊：不可切除的转移性黑色素瘤的治疗选择。
BioDrugs. 2016 Oct;30(5):461-468. doi: 10.1007/s40259-016-0189-y.
4
Talimogene laherparepvec (T-VEC) as cancer immunotherapy.塔利莫基因拉罗韦克（T-VEC）作为癌症免疫疗法。
Drugs Today (Barc). 2015 Sep;51(9):549-58. doi: 10.1358/dot.2015.51.9.2383044.
5
Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.塔利莫基因拉哈帕里韦克：一种用于黑色素瘤的溶瘤病毒疗法。
Ann Pharmacother. 2017 Aug;51(8):675-681. doi: 10.1177/1060028017702654. Epub 2017 Mar 28.
6
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.从一项多机构的 II 期研究看，黑色素瘤患者接受替莫唑胺拉帕替尼治疗后的全身和局部反应。
J Immunother Cancer. 2016 Mar 15;4:12. doi: 10.1186/s40425-016-0116-2. eCollection 2016.
7
An evaluation of talimogene laherparepvec for the treatment of melanoma.替莫唑胺胶束治疗恶性胶质瘤的临床研究进展
Expert Opin Biol Ther. 2020 Jan;20(1):9-14. doi: 10.1080/14712598.2020.1689951.
8
Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.对于在免疫检查点抑制剂和BRAF抑制剂治疗后疾病进展的黑色素瘤患者，talimogene laherparepvec的潜在临床及免疫治疗效用。
Melanoma Res. 2018 Jun;28(3):250-255. doi: 10.1097/CMR.0000000000000444.
9
A practical guide to the handling and administration of talimogene laherparepvec in Europe.欧洲塔利莫吉拉帕里韦克处理与给药实用指南
Onco Targets Ther. 2017 Aug 2;10:3867-3880. doi: 10.2147/OTT.S133699. eCollection 2017.
10
Pharmacy Operationalization of the Intralesional Oncolytic Immunotherapy Talimogene Laherparepvec.瘤内溶瘤免疫疗法Talimogene Laherparepvec的药学操作规范
Hosp Pharm. 2018 Oct;53(5):296-302. doi: 10.1177/0018578717749926. Epub 2018 Jan 10.

引用本文的文献

1
Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment.肿瘤性黑变病模拟替莫唑胺治疗后残留黑色素瘤。
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005257.

本文引用的文献

1
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.随机、开放标签的 II 期研究评估了替莫唑胺联合伊匹单抗与伊匹单抗单药治疗晚期不可切除黑色素瘤患者的疗效和安全性。
J Clin Oncol. 2018 Jun 10;36(17):1658-1667. doi: 10.1200/JCO.2017.73.7379. Epub 2017 Oct 5.
2
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.溶瘤病毒疗法可促进肿瘤内T细胞浸润并改善抗PD-1免疫疗法。
Cell. 2017 Sep 7;170(6):1109-1119.e10. doi: 10.1016/j.cell.2017.08.027.
3
Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.
在 IIIB/C 期和 IVM1a 期黑色素瘤患者中，talimogene laherparepvec 与粒细胞巨噬细胞集落刺激因子的疗效和安全性比较：III 期 OPTiM 试验的亚组分析
Onco Targets Ther. 2016 Nov 16;9:7081-7093. doi: 10.2147/OTT.S115245. eCollection 2016.
4
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy.进入临床：替莫唑胺（T-VEC），一种首创的肿瘤内溶瘤病毒治疗药物。
J Immunother Cancer. 2016 Sep 20;4:53. doi: 10.1186/s40425-016-0158-5. eCollection 2016.
5
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.在OPTiM III期临床试验中接受talimogene laherparepvec（T-VEC）治疗的黑色素瘤患者的临床反应模式。
Ann Surg Oncol. 2016 Dec;23(13):4169-4177. doi: 10.1245/s10434-016-5286-0. Epub 2016 Jun 24.
6
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.替莫唑胺胶丸联合放疗治疗恶性脑胶质瘤的疗效观察
J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.
7
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.瘤内注射 GM-CSF 编码溶瘤单纯疱疹病毒在 IIIc 期和 IV 期黑色素瘤患者中诱导的局部和远处免疫。
Ann Surg Oncol. 2010 Mar;17(3):718-30. doi: 10.1245/s10434-009-0809-6.
8
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).实体瘤新的疗效评价标准：修订的RECIST指南（第1.1版）
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
9
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.一项关于OncoVEXGM-CSF的I期研究，OncoVEXGM-CSF是一种表达粒细胞巨噬细胞集落刺激因子的第二代溶瘤单纯疱疹病毒。
Clin Cancer Res. 2006 Nov 15;12(22):6737-47. doi: 10.1158/1078-0432.CCR-06-0759.